<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891706</url>
  </required_header>
  <id_info>
    <org_study_id>FI-FIT001-001</org_study_id>
    <nct_id>NCT03891706</nct_id>
  </id_info>
  <brief_title>Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors</brief_title>
  <official_title>An Open, Single-center, Stage I Clinical Study of Individualized Tumor Specific TCR-T Cells in the Treatment of Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou FineImmune Biotechnology Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou FineImmune Biotechnology Co., LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells
      in the treatment of advanced Solid Tumor .

      The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in
      the treatment of advanced Solid Tumor .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open, single-center, phase I clinical trial which is aim to evaluate the
      safety and tolerability of tumor-specific TCR-T cells. In this study, these TCR-T cells will
      be multiplied, or grown, in the laboratory.Subjects will received TCR-T cells infusions twice
      at day 0 and day 14, with the use of IL-2 for 5 consecutive days after every cell infusion.
      Before the cells infusion, Subjects also received Flu/Cy chemotherapy regimen before the
      first TCR-T cell infusion: Fludarabine 25mg/m2/ d-iv-d4 ~ -d3 4 days ,Cyclophosphamide
      500mg/m2/ d-iv-d4 ~ -d3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>At least 45 days</time_frame>
    <description>Keep records the adverse events experienced by subjects in 30 days after the last infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>one year</time_frame>
    <description>DCR is defined as the proportion of patients with tumor size reduction(CR,PR) and stable (SD) assessed by RECIST 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS)</measure>
    <time_frame>two year</time_frame>
    <description>The time from the first injection of Investigational Product until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival(PFS)</measure>
    <time_frame>two year</time_frame>
    <description>PFS is defined as the time from the first injection of Investigational Product until objective tumor progression or death, whichever occurs first.Assessed by RECIST 1.1 and iRECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TCR-T cell infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will exposed to Individualized Tumor-t Cell Receptor (TCR) -Mediated T Cells therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tumor-specific TCR-T cells</intervention_name>
    <description>On day 0 and day 14, 0.5-5x10^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.</description>
    <arm_group_label>TCR-T cell infusion</arm_group_label>
    <other_name>TCR-T cells</other_name>
    <other_name>FIT-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .</description>
    <arm_group_label>TCR-T cell infusion</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 25mg/m2/ d.iv. -d4~ -d3 before the first cell infusion.</description>
    <arm_group_label>TCR-T cell infusion</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 500mg/m2/ d.iv. -d4~ -d3 before the first cell infusion.</description>
    <arm_group_label>TCR-T cell infusion</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18 and 70 years old, regardless of gender;

          2. Diagnosed as solid tumors by histopathology, and the tumor lesions could be detected
             or evaluated;

          3. Be after standard treatment or who lack effective treatment programs;

          4. Patients and their families were willing to participate in the clinical trial and
             signed the informed consent;

          5. Physical status: ECOG score 0-1;

          6. Expected survival time &gt; 3 months;

          7. HIV antibody negative;Hepatitis b surface antigen negative;Hepatitis c antibody
             negative;The results of blood routine and coagulation were roughly normal, lymphocyte
             &gt;0.8Ã—10^9/L, hemoglobin &gt;100g/L, and the pregnancy test of female patients with
             fertility potential was negative.

          8. Left ventricular ejection fraction 50% as indicated by cardiac ultrasound;Upper normal
             level of serum ALT/AST &lt; 2.5 times;Serum creatinine 1.6mg/dl;Total bilirubin 1.5mg/dl,
             subject's total bilirubin &lt; 3mg/dl except for Gilberts Syndrome;

          9. At least 4 weeks after the last systemic treatment, the patient's toxic and side
             effects must be restored to grade 1 or lower (except for alopecia or vitiligo).If the
             subject undergoes minor surgery within 3 weeks prior to enrollment, as long as all
             toxicity is recovered to level 1 or lower, the subject will meet the enrollment
             requirements.

         10. During the whole study period, patients can regularly visit the enrolled research
             institutions for relevant detection, evaluation and management;

         11. The patient is not allowed to use any anti-tumor drugs or treatments for 4 weeks prior
             to the infusion of TCR-T cells;

         12. Patients' tumor lesions can be obtained by surgery or puncture, and tumor infiltrating
             T cells can be successfully isolated from the obtained tumor tissue;

         13. T cells in patients' peripheral blood can effectively proliferate and expand by at
             least 10 times in the Pre-culture;

         14. The benefits of participating in the clinical trial outweigh the risks,which was
             evaluated by the researchers base on the status or condition of the patients.

        Exclusion Criteria:

          1. Any form of primary immunodeficiency disease (such as severe combined immunodeficiency
             disease);

          2. Experiencing moderate to severe infection or possible opportunistic infection;

          3. Patients with a history of autoimmunity (e.g., SLE, psoriasis, etc.);

          4. Acute systemic infection, coagulation dysfunction or other serious cardiopulmonary
             diseases;

          5. Patients who have is suffering a large amount of glucocorticoid or other
             immunosuppressive agents within 4 weeks;

          6. Be allergic to any drug used in this study;

          7. Central nervous system metastases patients with clinically unstable or acute
             meningitis (except these clinically stable after treatment) Clinical stability needs
             to be met as follows: 4 weeks at least before the trial treatment, 1) no new brain
             lesion or no expanded of the original lesions confirmed by MRI); 2) no hormone therapy
             for at least 2 weeks; 3) neurological symptoms have returned to baseline;

          8. For patients who suffered grade 3-4 immune-related adverse reactions of major organs
             after they received the treatment of PD-1 / PD-L1 antibody;

          9. Have exposed to any gene therapy products previously;

         10. Pregnant and lactating women, as well as male and female patients who could not
             cooperate with contraception during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penghui Zhou</last_name>
    <role>Study Director</role>
    <affiliation>Guangzhou FineImmune Biotechnology Co., LTD.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuzhi Pan</last_name>
    <phone>86-20-87343135</phone>
    <email>panxzh@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haiping Liu</last_name>
    <phone>020-31605836</phone>
    <email>liuhp11@fineimmu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Gaungdong</state>
        <zip>510700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuzhi Pan</last_name>
      <phone>86-20-87343135</phone>
      <email>panxzh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaoshi Zhang, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 24, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TCR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

